Handelsbanken Fonder AB Acquires 10,500 Shares of Solventum Corporation $SOLV

Handelsbanken Fonder AB lifted its holdings in shares of Solventum Corporation (NYSE:SOLV) by 28.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,300 shares of the company’s stock after buying an additional 10,500 shares during the period. Handelsbanken Fonder AB’s holdings in Solventum were worth $3,453,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Deseret Mutual Benefit Administrators boosted its holdings in shares of Solventum by 78.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after acquiring an additional 163 shares during the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum during the second quarter valued at approximately $28,000. MUFG Securities EMEA plc bought a new position in Solventum during the second quarter valued at approximately $31,000. State of Wyoming purchased a new stake in Solventum in the second quarter worth approximately $33,000. Finally, MTM Investment Management LLC bought a new stake in Solventum in the 2nd quarter worth approximately $40,000.

Solventum Stock Performance

NYSE:SOLV opened at $70.85 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23. The stock has a 50-day simple moving average of $78.24 and a two-hundred day simple moving average of $76.24. The firm has a market capitalization of $12.29 billion, a PE ratio of 7.99, a P/E/G ratio of 1.20 and a beta of 0.40. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $88.20.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the company earned $1.41 earnings per share. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has authorized a share buyback program on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on SOLV shares. Stifel Nicolaus increased their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Wells Fargo & Company reduced their price objective on Solventum from $86.00 to $83.00 and set an “equal weight” rating for the company in a research report on Friday, February 27th. BTIG Research reissued a “buy” rating and issued a $100.00 target price on shares of Solventum in a report on Friday, February 27th. Piper Sandler restated an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Finally, KeyCorp upped their price target on shares of Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $93.70.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.